Better Therapeutics Long Term Debt

The latest long-term debt for MCAD is $7.7M as of September 2023. That compares with $12M in the prior-year period — down 33.8% year over year. Investors often review this figure alongside Better Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, MCAD's long-term debt moved from $12M to $7.7M — a 33.8% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Better Therapeutics's operating scale or balance-sheet position.

A long-term debt figure of $7.7M for MCAD is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting MCAD's long-term debt ($7.7M), review year-over-year change from $12M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.